ZLY032 | CAS#2314465-67-1 | FFAR & PPAR agonist

MedKoo Cat#: 462928 | Name: ZLY032

Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

ZLY032 is a dual agonist of free fatty acid receptor 1 and peroxisome proliferator-activated receptor δ. It is selective for FFAR1 and PPARδ over PPARα and PPARγ. ZLY032 reduces blood glucose levels in an oral glucose tolerance test and decreases plasma total cholesterol and triglyceride levels in the ob/ob mouse model of metabolic disease. It reduces hepatic steatosis and plasma alanine transaminase and aspartate aminotransferase levels in a mouse model of non-alcoholic steatohepatitis induced by a methionine and choline-deficient diet at the same dose.

Chemical Structure

ZLY032

CAS#2314465-67-1

Theoretical Analysis

MedKoo Cat#: 462928

Name: ZLY032

CAS#: 2314465-67-1

Chemical Formula: C22H18F3NO4S

Exact Mass: 449.0909

Molecular Weight: 449.44

Elemental Analysis: C, 58.79; H, 4.04; F, 12.68; N, 3.12; O, 14.24; S, 7.13

Price and Availability

Size	Price	Availability
5mg	USD 350.00	2 Weeks
10mg	USD 550.00	2 Weeks
25mg	USD 950.00	2 Weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

No Data

Synonym

ZLY 032; ZLY-032;

IUPAC/Chemical Name

(S)-2-(6-((4-methyl-2-(4-(trifluoromethyl)phenyl)thiazol-5-yl)methoxy)-2,3-dihydrobenzofuran-3-yl)acetic acid

InChi Key

YBBZJHLFUPKHJD-CQSZACIVSA-N

InChi Code

InChI=1S/C22H18F3NO4S/c1-12-19(31-21(26-12)13-2-4-15(5-3-13)22(23,24)25)11-29-16-6-7-17-14(8-20(27)28)10-30-18(17)9-16/h2-7,9,14H,8,10-11H2,1H3,(H,27,28)/t14-/m1/s1

SMILES Code

CC1=C(COC2=CC=C3[C@@H](COC3=C2)CC(O)=O)SC(C4=CC=C(C=C4)C(F)(F)F)=N1

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>3 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 449.44 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Xu C, Gao X, Ren T, Geng H, Yang K, Huang Y, Zhang W, Hou S, Song A, Zhang Y, Zhao Q. The ADAM17 inhibitor ZLDI-8 sensitized hepatocellular carcinoma cells to sorafenib through Notch1-integrin β-talk. Pharmacol Res. 2024 May;203:107142. doi: 10.1016/j.phrs.2024.107142. Epub 2024 Mar 24. PMID: 38522759. 2: Lu H, Wu C, Jiang XW, Zhao Q. ZLDI-8 suppresses angiogenesis and vasculogenic mimicry in drug-resistant NSCLC in vitro and in vivo. Lung Cancer. 2023 Aug;182:107279. doi: 10.1016/j.lungcan.2023.107279. Epub 2023 Jun 14. PMID: 37364397. 3: Zhang Y, Xu C, Xu X, Ma L, Li R, Xu Z, Zhao Q. Pharmacokinetics, tissue distribution, and antitumor activity of a novel compound, NY-2, in non-small cell lung cancer. Front Pharmacol. 2023 Jan 16;13:1074576. doi: 10.3389/fphar.2022.1074576. PMID: 36726788; PMCID: PMC9884808. 4: Roubtsova A, Garçon D, Lacoste S, Chamberland A, Marcinkiewicz J, Métivier R, Sotin T, Paquette M, Bernard S, Cariou B, Le May C, Koschinsky ML, Seidah NG, Prat A. PCSK9 deficiency results in a specific shedding of excess LDLR in female mice only: Role of hepatic cholesterol. Biochim Biophys Acta Mol Cell Biol Lipids. 2022 Dec;1867(12):159217. doi: 10.1016/j.bbalip.2022.159217. Epub 2022 Aug 17. PMID: 35985474. 5: Lu HY, Chu HX, Tan YX, Qin XC, Liu MY, Li JD, Ren TS, Zhang YS, Zhao QC. Novel ADAM-17 inhibitor ZLDI-8 inhibits the metastasis of hepatocellular carcinoma by reversing epithelial-mesenchymal transition in vitro and in vivo. Life Sci. 2020 Mar 1;244:117343. doi: 10.1016/j.lfs.2020.117343. Epub 2020 Jan 21. PMID: 31978449. 6: Lu HY, Zu YX, Jiang XW, Sun XT, Liu TY, Li RL, Wu Q, Zhang YS, Zhao QC. Novel ADAM-17 inhibitor ZLDI-8 inhibits the proliferation and metastasis of chemo- resistant non-small-cell lung cancer by reversing Notch and epithelial mesenchymal transition in vitro and in vivo. Pharmacol Res. 2019 Oct;148:104406. doi: 10.1016/j.phrs.2019.104406. Epub 2019 Aug 20. PMID: 31442576. 7: Li DD, Zhao CH, Ding HW, Wu Q, Ren TS, Wang J, Chen CQ, Zhao QC. A novel inhibitor of ADAM17 sensitizes colorectal cancer cells to 5-Fluorouracil by reversing Notch and epithelial-mesenchymal transition in vitro and in vivo. Cell Prolif. 2018 Oct;51(5):e12480. doi: 10.1111/cpr.12480. Epub 2018 Aug 2. PMID: 30069943; PMCID: PMC6528951. 8: Zhang Y, Li D, Jiang Q, Cao S, Sun H, Chai Y, Li X, Ren T, Yang R, Feng F, Li BA, Zhao Q. Novel ADAM-17 inhibitor ZLDI-8 enhances the in vitro and in vivo chemotherapeutic effects of Sorafenib on hepatocellular carcinoma cells. Cell Death Dis. 2018 Jul 3;9(7):743. doi: 10.1038/s41419-018-0804-6. PMID: 29970890; PMCID: PMC6030059.